In order to explore the clinical medication law and mechanism of unusual psoriasis based on data mining and network pharmacology. We collected and screened the prescription data of Shaanxi Traditional Chinese Medicine Hospital Skin Disease Hospital Specialized Clinic patients with psoriasis vulgaris from 1 September 2022 to 1 March 2023, and entered them into Excel software to establish a standardised case database of psoriasis vulgaris by two persons alternately, and then carried out the drug association rule analysis on the case data by using the Chinese medicine inheritance computing platform (V3.0) and IBM SPSS Modeler 18.0 to obtain the core drugs and construct a network of "disease-core drug-component-target", and then analyse the core drugs and the drug association rules. We constructed a "disease-core drug-component-target" network and analysed the protein interaction network and enrichment of intersecting targets. Resultsly, 189 prescriptions and 134 flavours of traditional Chinese medicines were obtained through screening, with a cumulative frequency of 3020 times, of which 38 flavours were used ≥20 times; The analysis of drug-association rules (support degree of the Apriori algorithm ≥65%, confidence degree ≥85%) showed that the core medicines had the same effect as the core medicines ≥85%) showed that the core drug Lonicera japonica-Lianqiao-Angelica sinensis-Paeonia lactiflora- Glycyrrhiza glabra medicinal group had a high degree of support. After excluding licorice, the core drug was subjected to network pharmacological analysis of the core drug components. A total of 192 active ingredients of the core drug components were associated with the disease targets of psoriasis vulgaris. Then GO enrichment analysis and KEGG pathway enrichment analysis were performed. In conclusion, according to the psoriasis clinic based on the database to obtain the key active ingredients and main targets of the drugs, it was found that the core group of drugs may alleviate the clinical symptoms of psoriasis by inhibiting the pro-inflammatory pathway and restricting the function of intracellular nuclear factors. It is of reference value for the study of the law of medication and mechanism for the prevention and treatment of psoriasis of the common type of traditional Chinese medicine.

Fu Mingshan, Li Wenbin, Xie Jiayi, Li Yanni. Exploration on the Clinical Medication Pattern and Mechanism of Psoriasis Vulgaris Based on Data Mining and Network Pharmacology. International Journal of Frontiers in Medicine (2023), Vol. 5, Issue 12: 25-35. https://doi.org/10.25236/IJFM.2023.051205.

[1] April W. Armstrong, Charlotte Read. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review [J]. JAMA, 2020, 323(19):1945-1960. 

[2] Psoriasis Specialized Committee of the Chinese Medical Association Branch of Dermatology and Venereology. Chinese psoriasis diagnosis and treatment guidelines (2018 full version) [J]. Chinese Journal of Dermatology, 2019, 52(10):667-710. 

[3] Chinese Society of Dermatology and Venereology. Guidelines for biologic treatment of psoriasis in China (2021) [J]. Chinese Journal of Dermatology, 2021, 54(12):1033-1047. 

[4] Meng Shikang, Lin Zibei, Wang Yan, et al. Psoriasis therapy by Chinese medicine and modern agents [J]. Chinese medicine, 2018, 13(1):16. 

[5] National Pharmacopoeia Commission. Pharmacopoeia of the People's Republic of China: a part [M]. 2020 Edition. Beijing: China Pharmaceutical Science and Technology Press, 2020. 

[6] Zhong Gansheng, Yang Bochan. Zhong Gansheng, Yang Bochan. National Higher Education of Traditional Chinese Medicine Industry "14th Five-Year Plan" Planning Textbook of Traditional Chinese Medicine [M]. Beijing: China Press of Traditional Chinese Medicine, 2021:15-23. 

[7] Lu Hongji, Ma Shengsuo, Wu Qianxin, et al. Effect of Traditional Chinese Medicine on Psoriasis Vulgaris: A Meta-Analysis and Systematic Review [J]. Complementary medicine research, 2022, 30(1): 63-77. 

[8] Mou Yan, Li Fuqiu, Xu Yangchun, et al. Global trends in the incidence of psoriasis from 1990 to 2019 [J]. European journal of dermatology: EJD, 2022, 32(2):207-213. 

[9] Sun Xiaoying, Zhao Huaibo, Wang Ruiping, et al. Psoriasis complicated with metabolic disorder is associated with traditional Chinese medicine syndrome types: a hospital-based retrospective case-control study [J]. Current medical research and opinion, 2022, 39(1):21-21. 

[10] Singh Atul, Easwari T S. Recent Advances in Psoriasis Therapy: Trends and Future Prospects [J]. Current drug targets, 2021, 22(15):1760-1771. 

[11] Li Xiaohong, et al. Activation of the STING-IRF3 pathway involved in psoriasis with diabetes mellitus [J]. Journal of cellular and molecular medicine, 2022, 26(8):2139-2151. 

[12] Tsoukalas Dimitris, Fragoulakis Vassileios, Sarandi Evangelia, et al. Targeted Metabolomic Analysis of Serum Fatty Acids for the Prediction of Autoimmune Diseases [J]. Frontiers in molecular biosciences, 2019, 6:120. 

[13] Dimas Dimitris, Tomou Ekaterina-Michaela, Karamani Christina, et al. Melissa officinalis ssp. altissima extracts: A therapeutic approach targeting psoriasis in mice [J]. Journal of Ethnopharmacology, 2020, 246:112208. 

[14] Li Xia, Yang Qi, Zheng Jie, et al. Efficacy and Safety of a Topical moisturizer containing Linoleic Acid and Ceramide for Mild-To-Moderate Psoriasis Vulgaris: A Multicenter Randomized Controlled Trial [J]. Dermatologic therapy, 2020, 33(6):e14263-e14263. 

[15] Gubán B, Vas K, Balog Z, et al. Abnormal regulation of fibronectin production by fibroblasts in psoriasis.[J]. The British journal of dermatology, 2016, 174(3):533-541. 

[16] Koji Kamiya, Megumi Kishimoto, Junichi Sugai, et al. Risk Factors for the Development of Psoriasis [J]. International Journal of Molecular Sciences, 2019, 20(18):4347. 

[17] Chinese Society of Traditional Chinese Medicine, Dermatology Branch. Expert consensus on Chinese medicine treatment of psoriasis (2017 edition) [J]. Chinese Journal of Integrative Dermatology and Venereology, 2018, 17 (03): 273-277.